云顶新耀-B（01952.HK）今日盘中大涨5.23%，引起市场广泛关注。
消息面上，中金公司发布研报，维持云顶新耀"跑赢行业"评级，并大幅上调目标价133%至70港元。中金指出，云顶新耀战略聚焦肾病领域和mRNA肿瘤疫苗。在肾病治疗领域，公司除已上市的耐赋康外，还布局了新一代共价可逆BTK抑制剂EVER001。在mRNA肿瘤疫苗领域，个性化肿瘤疫苗EVM16的IIT研究已在国内启动，通用型现货肿瘤治疗性疫苗EVM14已获得美国FDA新药临床试验批准。中金认为，EVER001及mRNA肿瘤疫苗开始在估值中体现，这是上调目标价的主要原因。
此外，云顶新耀近期还公布了股权激励计划。公司于4月1日根据首次公开发行后购股权计划授出445万份购股权，行使价为55.61港元。同时，公司还根据首次公开发行前员工购股权计划授出115万份非关连奖励和55万份表现目标奖励。这一举措旨在吸引、留住和激励人才，进一步提升公司整体业务表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.